Rob ter Heine - Concepedia

Author

Rob ter Heine

Also Known As

R Ter Heine, R ter Heine, R. HEINE, R. Heine, R. Ter Heine, R. ter Heine, Rob Ter Heine, Rob Ter heine, Rob ter Heine, Rob ter Heine

233

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center Radboud Institute for Molecular Life Sciences Slotervaartziekenhuis Utrecht University

About

Rob ter Heine is an author at Radboud University Nijmegen specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	677
2	Engineering	3	3	83
3	Natural Sciences	2	2	151
4	Health Sciences	1	1	42
5	Public Health	1	1	68

Rob ter Heine

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography–triple quadrupole mass spectrometry Rob ter Heine, Hilde Rosing, E.C.M. van Gorp, Journal of Chromatography B Protease InhibitorsProteomic TechnologyBiochemistryDried Blood SpotsMedicine	2008	114
Model‐Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities Ron J. Keizer, Rob ter Heine, Adam Frymoyer, CPT Pharmacometrics & Systems Pharmacology Precision DosingModel-informed Precision DosingTranslational MedicineTherapeutic Drug MonitoringMedicine	2018	114
Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic Simone J.C.F.M. Moorlag, Esther Taks, Thijs ten Doesschate, Clinical Infectious Diseases	2022	91
Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non‐nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry Rob ter Heine, Carolien G. Alderden‐Los, Hilde Rosing, Rapid Communications in Mass Spectrometry	2007	84
Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors Roos L. Oostendorp, Alwin D. R. Huitema, Hilde Rosing, Clinical Cancer Research	2009	78
Effects of cytochrome P450 3A (CYP3A) and the drug transporters P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir RAB van Waterschoot, Rob ter Heine, Els Wagenaar, British Journal of Pharmacology	2010	69
Incidence and risk factors for nevirapine-associated rash Monique M. R. de Maat, Rob ter Heine, Jan W. Mulder, European Journal of Clinical Pharmacology Clinical EpidemiologyAntiviral TherapyAntiviral DrugPublic HealthRisk Factors	2003	68
Age, Weight, and <i>CYP2D6</i> Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children Bronner P. Gonçalves, Helmi Pett, Alfred B. Tiono, Antimicrobial Agents and Chemotherapy	2017	60
Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry Rob ter Heine, M. J. X. Hillebrand, Hilde Rosing, Journal of Pharmaceutical and Biomedical Analysis MedicineHuman RetrovirusBioanalysisMass SpectrometryAntiviral Therapy	2008	55
Intracellular and plasma steady‐state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre‐treated HIV‐infected patients Rob ter Heine, Jan W. Mulder, Eric C. M. Van Gorp, British Journal of Clinical Pharmacology	2010	48

Page 1